## Henryk Dreger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8095393/publications.pdf

Version: 2024-02-01

69 papers 2,603 citations

218677
26
h-index

197818 49 g-index

71 all docs

71 docs citations

71 times ranked

4565 citing authors

#	Article	IF	Citations
1	Phasic left atrial strain analysis to discriminate cardiac amyloidosis in patients with unclear thick heart pathology. European Heart Journal Cardiovascular Imaging, 2021, 22, 680-687.	1.2	26
2	Clinical pre-test probability for obstructive coronary artery disease: insights from the European DISCHARGE pilot study. European Radiology, 2021, 31, 1471-1481.	4.5	10
3	Pilot study of the multicentre DISCHARGE Trial: image quality and protocol adherence results of computed tomography and invasive coronary angiography. European Radiology, 2020, 30, 1997-2009.	4.5	3
4	Mortality and morbidity 1 year after stopping a remote patient management intervention: extended follow-up results from the telemedical interventional management in patients with heart failure II (TIM-HF2) randomised trial. The Lancet Digital Health, 2020, 2, e16-e24.	12.3	31
5	Associations of 2D speckle tracking echocardiography-based right heart deformation parameters and invasively assessed hemodynamic measurements in patients with pulmonary hypertension. Cardiovascular Ultrasound, 2020, 18, 13.	1.6	8
6	Health-related qualify of life, angina type and coronary artery disease in patients with stable chest pain. Health and Quality of Life Outcomes, 2020, 18, 140.	2.4	14
7	Automated quantification of mitral valve tenting volume in functional mitral regurgitation by threeâ€dimensional echocardiography. Echocardiography, 2020, 37, 1043-1048.	0.9	4
8	Impact of inferior caval valve implantation on severity of tricuspid regurgitation and right heart function. Echocardiography, 2020, 37, 999-1007.	0.9	6
9	Treatment of Severe TRIcuspid Regurgitation in Patients with Advanced Heart Failure with CAval Vein Implantation of the Edwards Sapien XT VALve (TRICAVAL): a randomised controlled trial. EuroIntervention, 2020, 15, 1506-1513.	3.2	42
10	Acute Myocardial Infarction Admissions in Berlin During the COVID-19 Pandemic. Deutsches Ärzteblatt International, 2020, 117, 597-598.	0.9	13
11	Inferior Caval Valve Implantation Versus Optimal Medical Therapy for Severe Tricuspid Regurgitation. Journal of the American College of Cardiology, 2019, 74, 473-475.	2.8	9
12	Sex-specific metabolic and functional differences in human umbilical vein endothelial cells from twin pairs. Atherosclerosis, 2019, 291, 99-106.	0.8	31
13	Dressler Syndrome in Anterior Myocardial Infarction Due To Traumatic Coronary Artery Dissection. Deutsches Ärzteblatt International, 2019, 116, 562.	0.9	1
14	Caval Valve Implantation for Treatment of Severe Tricuspid Regurgitation. Journal of the American College of Cardiology, 2018, 71, 1183-1184.	2.8	17
15	Percutaneous biventricular Impella support in therapy-refractory cardiogenic shock. Heart and Lung: Journal of Acute and Critical Care, 2018, 47, 250-252.	1.6	17
16	Interventional Treatment of Severe Tricuspid Regurgitation. Circulation: Cardiovascular Interventions, 2018, 11, e006061.	3.9	101
17	Right heart function in impaired left ventricular diastolic function: 2D speckle tracking echocardiography–based and Doppler tissue imaging–based analysis of right atrial and ventricular function. Echocardiography, 2018, 35, 47-55.	0.9	13
18	Midregional pro-A-type natriuretic peptide as part of a dual biomarker strategy for the early rule out of non-ST segment elevation acute coronary syndrome – The WilCop study. International Journal of Cardiology, 2018, 273, 243-248.	1.7	2

#	Article	IF	Citations
19	Normative reference data, determinants, and clinical implications of right atrial reservoir function in women assessed by 2D speckleâ€tracking echocardiography. Echocardiography, 2018, 35, 1542-1549.	0.9	17
20	Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial. Lancet, The, 2018, 392, 1047-1057.	13.7	467
21	Valve in valve implantation of the CoreValve Evolut R in degenerated surgical aortic valves. Cardiology Journal, 2018, 25, 301-307.	1.2	3
22	Lipoprotein apheresis in patients with peripheral artery disease and lipoprotein(a)-hyperlipoproteinemia: 2-year follow-up of a prospective single center study. Atherosclerosis Supplements, 2017, 30, 174-179.	1.2	21
23	Mid-regional pro-adrenomedullin (MR-proADM) and mid-regional pro-atrial natriuretic peptide (MR-proANP) in severe aortic valve stenosis: association with outcome after transcatheter aortic valve implantation (TAVI). Clinical Chemistry and Laboratory Medicine, 2017, 55, 275-283.	2.3	11
24	Left atrial strain predicts hemodynamic parameters in cardiovascular patients. Echocardiography, 2017, 34, 1170-1178.	0.9	28
25	Computed tomography versus invasive coronary angiography: design and methods of the pragmatic randomised multicentre DISCHARGE trial. European Radiology, 2017, 27, 2957-2968.	4.5	33
26	Levels of Circulating Intermediate Monocytes Decrease after Aortic Valve Replacement in Patients with Severe Aortic Stenosis. Thrombosis and Haemostasis, 2017, 117, 2346-2355.	3.4	13
27	Optimized Implantation Height of the Edwards SAPIEN 3 Valve to Minimize Pacemaker Implantation After TAVI. Journal of Interventional Cardiology, 2016, 29, 370-374.	1.2	38
28	Improved Left Ventricular Structure and Function After Successful Kidney Transplantation. Kidney and Blood Pressure Research, 2016, 41, 701-709.	2.0	41
29	Evaluation of computed tomography in patients with atypical angina or chest pain clinically referred for invasive coronary angiography: randomised controlled trial. BMJ, The, 2016, 355, i5441.	6.0	86
30	Epigenetic suppression of iNOS expression in human endothelial cells: A potential role of Ezh2-mediated H3K27me3. Genomics, 2016, 107, 145-149.	2.9	16
31	Prevalence of E/A Wave Fusion and A Wave Truncation in DDD Pacemaker Patients with Complete AV Block under Nominal AV Intervals. PLoS ONE, 2015, 10, e0116075.	2.5	3
32	Midterm echocardiographic follow-up of cardiac function after living kidney donation. Clinical Nephrology, 2015, 83 (2015), 253-261.	0.7	7
33	Cardiac and renal function in a large cohort of amateur marathon runners. Cardiovascular Ultrasound, 2015, 13, 13.	1.6	49
34	Lipoprotein apheresis in patients with peripheral artery disease and hyperlipoproteinemia(a). Atherosclerosis Supplements, 2015, 18, 187-193.	1.2	7
35	Efficacy of optimal medical therapy and cardiac resynchronization therapy upgrade in patients with pacemaker-induced cardiomyopathy. Journal of Interventional Cardiac Electrophysiology, 2015, 44, 289-296.	1.3	16
36	Galectin-3 predicts short- and long-term outcome in patients undergoing transcatheter aortic valve implantation (TAVI). International Journal of Cardiology, 2014, 177, 912-917.	1.7	37

#	Article	lF	Citations
37	Longâ€Term Doppler Hemodynamics and Effective Orifice Areas of Edwards <scp>SAPIEN </scp> and Medtronic CoreValve Prostheses after <scp>TAVI </scp> . Echocardiography, 2014, 31, 302-310.	0.9	7
38	Exercise-induced changes of left ventricular diastolic function in postmenopausal amateur marathon runners: assessment by echocardiography and cardiac biomarkers. European Journal of Preventive Cardiology, 2014, 21, 782-790.	1.8	17
39	Left atrial mechanics predict the success of pulmonary vein isolation in patients with atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2014, 40, 53-62.	1.3	20
40	Not left ventricular lead position, but the extent of immediate asynchrony reduction predicts long-term response to cardiac resynchronization therapy. Clinical Research in Cardiology, 2014, 103, 457-466.	3.3	6
41	Electrocardiographic monitoring during marathon running: a proof of feasibility for a new telemedical approach. European Journal of Preventive Cardiology, 2014, 21, 32-37.	1.8	11
42	Recovery of left ventricular and left atrial mechanics in various entities of aortic stenosis 12 months after TAVI. European Heart Journal Cardiovascular Imaging, 2014, 15, 389-398.	1.2	47
43	Echocardiographic follow-up of patients with systemic sclerosis by 2D speckle tracking echocardiography of the left ventricle. Cardiovascular Ultrasound, 2014, 12, 13.	1.6	32
44	Complete Atrioventricular Block after TAVI: When Is Pacemaker Implantation Safe?. PACE - Pacing and Clinical Electrophysiology, 2013, 36, 898-903.	1.2	15
45	Short-Term Effects of Transcatheter Aortic Valve Implantation on Left Atrial Mechanics and Left Ventricular Diastolic Function. Journal of the American Society of Echocardiography, 2013, 26, 64-71.e2.	2.8	33
46	Left Ventricular Asynchrony in Patients with Right Bundle Branch Block and Normal Ejection Fraction. PACE - Pacing and Clinical Electrophysiology, 2013, 36, 63-68.	1.2	2
47	Perforation of the right ventricle by bone cement: a rare complication of kyphoplasty. European Heart Journal, 2013, 34, 1203-1203.	2.2	6
48	Epigenetic Regulation of Cell Adhesion and Communication by Enhancer of Zeste Homolog 2 in Human Endothelial Cells. Hypertension, 2012, 60, 1176-1183.	2.7	45
49	Attenuation of Early Atherogenesis in Low-Density Lipoprotein Receptor–Deficient Mice by Proteasome Inhibition. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 1418-1426.	2.4	25
50	Doppler haemodynamics and effective orifice areas of Edwards SAPIEN and CoreValve transcatheter aortic valves. European Heart Journal Cardiovascular Imaging, 2012, 13, 690-696.	1.2	26
51	Two-dimensional speckle tracking of the left ventricle in patients with systemic sclerosis for an early detection of myocardial involvement. European Heart Journal Cardiovascular Imaging, 2012, 13, 863-870.	1.2	58
52	Dyssynchrony parameter-guided interventricular delay programming. Europace, 2012, 14, 696-702.	1.7	7
53	Pacing-induced cardiomyopathy in patients with right ventricular stimulation for >15 years. Europace, 2012, 14, 238-242.	1.7	99
54	Echocardiographic diagnosis, management and monitoring of pulmonary embolism with right heart thrombus in a patient with myotonic dystrophy: a case report. Cardiovascular Ultrasound, 2010, 8, 18.	1.6	5

#	Article	IF	CITATIONS
55	Early right ventricular systolic dysfunction in patients with systemic sclerosis without pulmonary hypertension: a Doppler Tissue and Speckle Tracking echocardiography study. Cardiovascular Ultrasound, 2010, 8, 3.	1.6	57
56	Successful reduction of intraventricular asynchrony is associated with superior response to cardiac resynchronization therapy. Cardiovascular Ultrasound, 2010, 8, 35.	1.6	9
57	ls Antiarrhythmia Device Implantation Safe Under Dual Antiplatelet Therapy?. PACE - Pacing and Clinical Electrophysiology, 2010, 33, 394-399.	1.2	25
58	Protection of vascular cells from oxidative stress by proteasome inhibition depends on Nrf2. Cardiovascular Research, 2010, 85, 395-403.	3.8	82
59	Chronotropic incompetence: a never-ending story. Europace, 2010, 12, 464-465.	1.7	2
60	Nrf2-dependent upregulation of antioxidative enzymes: a novel pathway for proteasome inhibitor-mediated cardioprotection. Cardiovascular Research, 2009, 83, 354-361.	3.8	185
61	Human-specific induction of glutathione peroxidase-3 by proteasome inhibition in cardiovascular cells. Free Radical Biology and Medicine, 2009, 47, 1652-1660.	2.9	18
62	Transesophageal echocardiography in patients with cryptogenic cerebral ischemia. Cardiovascular Ultrasound, 2009, 7, 15.	1.6	33
63	A modified echocardiographic protocol with intrinsic plausibility control to determine intraventricular asynchrony based on TDI and TSI. Cardiovascular Ultrasound, 2009, 7, 46.	1.6	6
64	Myocardial Function in Older Male Amateur Marathon Runners: Assessment by Tissue Doppler Echocardiography, Speckle Tracking, and Cardiac Biomarkers. Journal of the American Society of Echocardiography, 2009, 22, 803-809.	2.8	60
65	Implementation of seven echocardiographic parameters of myocardial asynchrony to improve the long-term response rate of cardiac resynchronization therapy (CRT). Cardiovascular Ultrasound, 2008, 6, 58.	1.6	4
66	Characteristics of Catechin- and Theaflavin-Mediated Cardioprotection. Experimental Biology and Medicine, 2008, 233, 427-433.	2.4	39
67	Suppression of Cardiomyocyte Hypertrophy by Inhibition of the Ubiquitin-Proteasome System. Hypertension, 2008, 51, 302-308.	2.7	90
68	Molecular targets of tea polyphenols in the cardiovascular system. Cardiovascular Research, 2007, 73, 348-358.	3.8	208
69	Nontoxic proteasome inhibition activates a protective antioxidant defense response in endothelial cells. Free Radical Biology and Medicine, 2006, 40, 2232-2241.	2.9	83